• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

化学特征描绘了阿尔茨海默病谱系中异质性淀粉样斑块群体。

Chemical signatures delineate heterogeneous amyloid plaque populations across the Alzheimer's disease spectrum.

作者信息

Koutarapu Srinivas, Ge Junyue, Dulewicz Maciej, Srikrishna Meera, Szadziewska Alicja, Wood Jack, Blennow Kaj, Zetterberg Henrik, Michno Wojciech, Ryan Natalie S, Lashley Tammaryn, Savas Jeffrey, Schöll Michael, Hanrieder Jörg

机构信息

Department of Psychiatry and Neurochemistry, Sahlgrenska Academy, University of Gothenburg, Mölndal, Sweden.

Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden.

出版信息

bioRxiv. 2024 Jun 3:2024.06.03.596890. doi: 10.1101/2024.06.03.596890.

DOI:10.1101/2024.06.03.596890
PMID:
38895368
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11185524/
Abstract

Amyloid plaque deposition is recognized as the primary pathological hallmark of Alzheimer's disease(AD) that precedes other pathological events and cognitive symptoms. Plaque pathology represents itself with an immense polymorphic variety comprising plaques with different stages of amyloid fibrillization ranging from diffuse to fibrillar, mature plaques. The association of polymorphic Aβ plaque pathology with AD pathogenesis, clinical symptoms and disease progression remains unclear. Advanced chemical imaging tools, such as functional amyloid microscopy combined with MALDI mass spectrometry imaging (MSI), are now enhanced by deep learning algorithms. This integration allows for precise delineation of polymorphic plaque structures and detailed identification of their associated Aβ compositions. We here set out to make use of these tools to interrogate heterogenic plaque types and their associated biochemical architecture. Our findings reveal distinct Aβ signatures that differentiate diffuse plaques from fibrilized ones, with the latter showing substantially higher levels of Aβx-40. Notably, within the fibrilized category, we identified a distinct subtype known as coarse-grain plaques. Both in sAD and fAD brain tissue, coarse grain plaques contained more Aβx-40 and less Aβx-42 compared with cored plaques. The coarse grain plaques in both sAD and fAD also showed higher levels of neuritic content including paired helical filaments (PHF-1)/phosphorylated phospho Tau-immunopositive neurites. Finally, the Aβ peptide content in coarse grain plaques resembled that of vascular Aβ deposits (CAA) though with relatively higher levels of Aβ1-42 and pyroglutamated Aβx-40 and Aβx-42 species in coarse grain plaques. This is the first of its kind study on spatial biochemical characterization of different plaque morphotypes demonstrating the potential of the correlative imaging techniques used that further increase the understanding of heterogeneous AD pathology. Linking the biochemical characteristics of amyloid plaque polymorphisms with various AD etiologies and toxicity mechanisms is crucial. Understanding the connection between plaque structure and disease pathogenesis can enhance our insights. This knowledge is particularly valuable for developing and advancing novel, amyloid-targeting therapeutics.

摘要

淀粉样斑块沉积被认为是阿尔茨海默病(AD)的主要病理标志,早于其他病理事件和认知症状。斑块病理学表现出巨大的多态性,包括从弥漫性到纤维状、成熟斑块等不同淀粉样纤维化阶段的斑块。多态性Aβ斑块病理学与AD发病机制、临床症状和疾病进展之间的关联仍不清楚。先进的化学成像工具,如功能淀粉样显微镜与基质辅助激光解吸电离质谱成像(MSI)相结合,现在通过深度学习算法得到了增强。这种整合允许精确描绘多态性斑块结构并详细识别其相关的Aβ组成。我们在此着手利用这些工具来研究异质性斑块类型及其相关的生化结构。我们的研究结果揭示了不同的Aβ特征,这些特征将弥漫性斑块与纤维化斑块区分开来,后者显示出显著更高水平的Aβx-40。值得注意的是,在纤维化类别中,我们鉴定出一种独特的亚型,称为粗颗粒斑块。在散发性AD(sAD)和家族性AD(fAD)脑组织中,与有核心斑块相比,粗颗粒斑块含有更多的Aβx-40和更少的Aβx-42。sAD和fAD中的粗颗粒斑块还显示出更高水平的神经突成分,包括双螺旋丝(PHF-1)/磷酸化磷酸化tau免疫阳性神经突。最后,粗颗粒斑块中的Aβ肽含量类似于血管Aβ沉积物(CAA),尽管粗颗粒斑块中Aβ1-42以及焦谷氨酸化Aβx-40和Aβx-42物种的水平相对较高。这是首次对不同斑块形态类型进行空间生化特征研究,证明了所使用的相关成像技术的潜力,进一步加深了对异质性AD病理学的理解。将淀粉样斑块多态性的生化特征与各种AD病因和毒性机制联系起来至关重要。理解斑块结构与疾病发病机制之间的联系可以增强我们的洞察力。这些知识对于开发和推进新型淀粉样蛋白靶向疗法特别有价值。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3ebe/11185524/6a345c984c9c/nihpp-2024.06.03.596890v1-f0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3ebe/11185524/f638af752fb4/nihpp-2024.06.03.596890v1-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3ebe/11185524/4b2f2f969c07/nihpp-2024.06.03.596890v1-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3ebe/11185524/fbcad9899a3a/nihpp-2024.06.03.596890v1-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3ebe/11185524/48aa9432afb0/nihpp-2024.06.03.596890v1-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3ebe/11185524/250e98ae9434/nihpp-2024.06.03.596890v1-f0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3ebe/11185524/6a345c984c9c/nihpp-2024.06.03.596890v1-f0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3ebe/11185524/f638af752fb4/nihpp-2024.06.03.596890v1-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3ebe/11185524/4b2f2f969c07/nihpp-2024.06.03.596890v1-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3ebe/11185524/fbcad9899a3a/nihpp-2024.06.03.596890v1-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3ebe/11185524/48aa9432afb0/nihpp-2024.06.03.596890v1-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3ebe/11185524/250e98ae9434/nihpp-2024.06.03.596890v1-f0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3ebe/11185524/6a345c984c9c/nihpp-2024.06.03.596890v1-f0006.jpg

相似文献

1
Chemical signatures delineate heterogeneous amyloid plaque populations across the Alzheimer's disease spectrum.化学特征描绘了阿尔茨海默病谱系中异质性淀粉样斑块群体。
bioRxiv. 2024 Jun 3:2024.06.03.596890. doi: 10.1101/2024.06.03.596890.
2
Pyroglutamation of amyloid-βx-42 (Aβx-42) followed by Aβ1-40 deposition underlies plaque polymorphism in progressing Alzheimer's disease pathology.淀粉样蛋白-βx-42(Aβx-42)的焦谷氨酸化,随后是 Aβ1-40 的沉积,是进行性阿尔茨海默病病理学中斑块多态性的基础。
J Biol Chem. 2019 Apr 26;294(17):6719-6732. doi: 10.1074/jbc.RA118.006604. Epub 2019 Feb 27.
3
Chemical imaging of evolving amyloid plaque pathology and associated Aβ peptide aggregation in a transgenic mouse model of Alzheimer's disease.阿尔茨海默病转基因小鼠模型中淀粉样斑块病变和相关 Aβ 肽聚集的化学成像。
J Neurochem. 2020 Mar;152(5):602-616. doi: 10.1111/jnc.14888. Epub 2019 Nov 6.
4
Correlative Chemical Imaging Identifies Amyloid Peptide Signatures of Neuritic Plaques and Dystrophy in Human Sporadic Alzheimer's Disease.相关化学成像鉴定出人类散发性阿尔茨海默病神经原纤维缠结斑块和营养不良的淀粉样肽特征。
Brain Connect. 2023 Jun;13(5):297-306. doi: 10.1089/brain.2022.0047. Epub 2022 Oct 7.
5
Chemical traits of cerebral amyloid angiopathy in familial British-, Danish-, and non-Alzheimer's dementias.家族性英国型、丹麦型和非阿尔茨海默病痴呆症的脑淀粉样血管病的化学特征。
J Neurochem. 2022 Nov;163(3):233-246. doi: 10.1111/jnc.15694. Epub 2022 Sep 25.
6
Post-mortem analyses of PiB and flutemetamol in diffuse and cored amyloid-β plaques in Alzheimer's disease.阿尔茨海默病弥散和核心淀粉样-β斑块中 PiB 和 flutemetamol 的死后分析。
Acta Neuropathol. 2020 Oct;140(4):463-476. doi: 10.1007/s00401-020-02175-1. Epub 2020 Aug 9.
7
Structural amyloid plaque polymorphism is associated with distinct lipid accumulations revealed by trapped ion mobility mass spectrometry imaging.结构淀粉样斑块多态性与被捕获离子淌度质谱成像显示的不同脂质蓄积相关。
J Neurochem. 2022 Feb;160(4):482-498. doi: 10.1111/jnc.15557. Epub 2021 Dec 26.
8
Neuritic Plaques - Gateways to Understanding Alzheimer's Disease.神经炎性斑块——理解阿尔茨海默病的关键切入点
Mol Neurobiol. 2024 May;61(5):2808-2821. doi: 10.1007/s12035-023-03736-7. Epub 2023 Nov 8.
9
The coarse-grained plaque: a divergent Aβ plaque-type in early-onset Alzheimer's disease.粗颗粒斑块:早发性阿尔茨海默病中一种不同的 Aβ 斑块类型。
Acta Neuropathol. 2020 Dec;140(6):811-830. doi: 10.1007/s00401-020-02198-8. Epub 2020 Sep 14.
10
Mass Spectrometry Imaging in Alzheimer's Disease.阿尔茨海默病的质谱成像。
Brain Connect. 2023 Aug;13(6):319-333. doi: 10.1089/brain.2022.0057. Epub 2023 Apr 24.

本文引用的文献

1
Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial.多奈哌齐治疗早期症状性阿尔茨海默病的随机临床试验。
JAMA. 2023 Aug 8;330(6):512-527. doi: 10.1001/jama.2023.13239.
2
Pyroglutamate-modified amyloid β(3-42) monomer has more β-sheet content than the amyloid β(1-42) monomer.焦谷氨酸修饰的淀粉样β(3-42)单体比淀粉样β(1-42)单体具有更多的β-折叠结构。
Phys Chem Chem Phys. 2023 Jun 21;25(24):16483-16491. doi: 10.1039/d2cp05961d.
3
Lecanemab in Early Alzheimer's Disease.早期阿尔茨海默病中的lecanemab
N Engl J Med. 2023 Jan 5;388(1):9-21. doi: 10.1056/NEJMoa2212948. Epub 2022 Nov 29.
4
Population pharmacokinetic-pharmacodynamic analyses of amyloid positron emission tomography and plasma biomarkers for lecanemab in subjects with early Alzheimer's disease.早期阿尔茨海默病患者淀粉样蛋白正电子发射断层扫描和血浆生物标志物的群体药代动力学-药效学分析。
CPT Pharmacometrics Syst Pharmacol. 2022 Dec;11(12):1578-1591. doi: 10.1002/psp4.12862. Epub 2022 Sep 27.
5
Chemical traits of cerebral amyloid angiopathy in familial British-, Danish-, and non-Alzheimer's dementias.家族性英国型、丹麦型和非阿尔茨海默病痴呆症的脑淀粉样血管病的化学特征。
J Neurochem. 2022 Nov;163(3):233-246. doi: 10.1111/jnc.15694. Epub 2022 Sep 25.
6
The AHEAD 3-45 Study: Design of a prevention trial for Alzheimer's disease.AHEAD 3-45 研究:阿尔茨海默病预防试验设计。
Alzheimers Dement. 2023 Apr;19(4):1227-1233. doi: 10.1002/alz.12748. Epub 2022 Aug 15.
7
Pyroglutamate Aβ cascade as drug target in Alzheimer's disease.焦谷氨酸 Aβ级联作为阿尔茨海默病的药物靶点。
Mol Psychiatry. 2022 Apr;27(4):1880-1885. doi: 10.1038/s41380-021-01409-2. Epub 2021 Dec 8.
8
Following spatial Aβ aggregation dynamics in evolving Alzheimer's disease pathology by imaging stable isotope labeling kinetics.通过示踪动力学成像研究阿尔茨海默病病变中淀粉样蛋白的空间聚集动力学。
Sci Adv. 2021 Jun 16;7(25). doi: 10.1126/sciadv.abg4855. Print 2021 Jun.
9
The PrecivityAD™ test: Accurate and reliable LC-MS/MS assays for quantifying plasma amyloid beta 40 and 42 and apolipoprotein E proteotype for the assessment of brain amyloidosis.PrecivityAD™ 测试:用于定量检测血浆淀粉样蛋白β 40 和 42 以及载脂蛋白 E 蛋白型的准确可靠的 LC-MS/MS 分析方法,用于评估脑淀粉样变性。
Clin Chim Acta. 2021 Aug;519:267-275. doi: 10.1016/j.cca.2021.05.011. Epub 2021 May 17.
10
A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody.一项针对早期阿尔茨海默病的仑卡奈单抗(抗 Aβ 原纤维抗体)的随机、双盲、2b 期概念验证临床试验。
Alzheimers Res Ther. 2021 Apr 17;13(1):80. doi: 10.1186/s13195-021-00813-8.